Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP Images)
April 23, 2024 11:28 AM EDT
R&D
Pharma

No­var­tis’ sim­pli­fied strat­e­gy takes shape as the com­pa­ny seeks for­mer Bris­tol My­ers CEO as chair

Kyle LaHucik

Senior Reporter

No­var­tis ap­pears head­ed in the right di­rec­tion now that San­doz has been spun out, op­er­a­tions have been stream­lined and the Swiss com­pa­ny is re­port­ing high­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times